Last Updated: September 24, 2026

Details for Patent: 11,717,571


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,717,571 protect, and when does it expire?

Patent 11,717,571 protects NEFFY and is included in one NDA.

This patent has eighty-five patent family members in thirty-three countries.

Summary for Patent: 11,717,571
Title:Intranasal epinephrine formulations and methods for the treatment of disease
Abstract:Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
Inventor(s):Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
Assignee: Aegis Therapeutics LLC
Application Number:US18/049,936
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,717,571
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device;

Drugs Protected by US Patent 11,717,571

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ars Pharms Operation NEFFY epinephrine SPRAY;NASAL 214697-002 Mar 5, 2025 RX Yes Yes 11,717,571 ⤷  Start Trial NASAL ADMINISTRATION OF EPINEPHRINE FOR THE TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS ⤷  Start Trial
Ars Pharms Operation NEFFY epinephrine SPRAY;NASAL 214697-001 Aug 9, 2024 RX Yes Yes 11,717,571 ⤷  Start Trial NASAL ADMINISTRATION OF EPINEPHRINE FOR THE TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,717,571

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3678649 ⤷  Start Trial 301317 Netherlands ⤷  Start Trial
European Patent Office 3678649 ⤷  Start Trial CA 2025 00007 Denmark ⤷  Start Trial
European Patent Office 3678649 ⤷  Start Trial PA2025507 Lithuania ⤷  Start Trial
European Patent Office 3678649 ⤷  Start Trial C20250011 Finland ⤷  Start Trial
European Patent Office 3678649 ⤷  Start Trial 122025000010 Germany ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.